safety of glp-1 receptor agonists Potential Use and GIP/GLP-1 for Respiratory Disorders: Where Are We at? There has been a drug

Sources Deane, A

In late-stage trials, people taking orforglipron lost an average of about 12% of their body weight over roughly 72 weeks , and head-to-head studies suggest it may outperform standard oral semaglutide tablets (Rybelsus) in both weight loss and blood sugar control

Thymus, bone marrow, spleen, mesenteric lymph nodes, brachial/axillary lymph nodes, inguinal lymph nodes, and PBMCs express low levels of Glp1r (29, 33, 34)

In collaboration with scientists at CU Boulder and Colorado State University, Paynes lab is part of a moonshot project funded by the federal government aimed at developing a regenerative approach to cure OA